All posts by Genetic Signatures

Genetic Signatures exhibiting at the 33rd ASM Clinical Virology Symposium (CVS) Savannah, Georgia, United States, 07-10 May 2017.

By | Latest News | No Comments

Genetic Signatures will be exhibiting at the 33rd ASM Clinical Virology Symposium (CVS) Savannah, Georgia, United States, 07-10 May 2017.

Presented by ASM- The Clinical Virology Symposium is a 3-day event highlighting the relationship between rapid viral diagnosis, clinical course of viral infections and preventive and therapeutic modalities for viral infections being the theme of this premier meeting. Discussion of timely topics by renowned scientists assures that this symposium will be informative and engaging, while newly acquired information about clinically relevant viral infections will be useful to practicing physicians who can apply this knowledge in a clinical setting.

Visit Genetic Signatures at Booth #435 at CVS 2017 for more information.

Click here to visit the ASM website for more information on ASM Clinical Virology Symposium 2017


 About ASM Clinical Virology Symposium: ASM Clinical Virology Symposium is led by biomedical scientists engaged in research as well as primary care physicians and laboratory professions involved with patient care. This international symposium will provide an unmatched forum for the meaningful exchange of ideas dealing with viral infections.

Genetic Signatures Featured in Latest GenomeWeb Article

By | ASX Announcements, Latest News | No Comments

GenomeWeb, the largest online newsroom focused on advanced molecular research tools, has featured Genetic Signatures and 3base™ technology, in an article about the company’s continued global market rollout of their existing and new suite of products. The new 3base™ multiplex PCR tests include an assay for detecting sexually transmitted infections and another that tests for all flaviviruses and alphaviruses. These assays complement Genetic Signatures’ tests already available which include assays for enteric and respiratory infections.  The GenomeWeb article highlighted Genetic Signatures’ recent clinical trial of their new EasyScreenTM Flavivirus/Alphavirus Detection kit, which was presented at the infectious diseases conference, ECCMID, in April 2017 (Vienna, Austria).  The article also discussed the ongoing global expansion strategy including the progress of regulatory approval in Australia and a CE-IVD marking of a number of products in the coming months.


 

Read the full article here

Genetic Signatures’ CSO presenting on the development of 3base™ Flavivirus/Alphavirus assay at ECCMID 2017 Vienna, Austria

By | Latest News | No Comments

Genetic Signatures’ Chief Scientific Officer, Dr Doug Millar, will be presenting at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on the 23rd April 2017 in Vienna, Austria.

Dr Millar will present results on the development of a 3base™ Flavivirus and Alphavirus Detection kit. The test allows for the detection of 15 of the most common flavivirus and alphavirus infections in the world, including dengue, West Nile virus, Zika, yellow fever virus, and chikungunya.

“Our novel 3baseTM technology allows for screening of diverse families of viruses in a single assay. The simultaneous screening of these flavivirus and alphavirus groups will provide faster results thus allowing for more effective treatment and reduce the risk of transmission to healthy individuals” said Dr Millar.


Slide1We invite you to hear Dr Millar’s presentation at ECCMID 2017

Session: New approaches in molecular diagnostic virology    

Location Hall C: April 23rd, 2017 at 14.30-15.30 (CEST).

Dr. Millar and Genetic Signatures’ CEO, Dr. Melki, will both be present for the duration of the conference at booth #137. They will be available to discuss Genetic Signatures’ suite of products for the detection of infectious diseases, including flavivirus and alphavirus as well as reagents for diagnosing bacterial, viral and protozoan causes of gastroenteritis, respiratory infections, and sexually transmitted infections.

Visit Genetic Signatures at Booth #137 at ECCMID 2017 for more information.

Click here to visit ECCMID 2017


About EasyScreen™ Flavivirus/Alphavirus Detection Kit: The EasyScreen™ Flavivirus/Alphavirus Detection Kit includes targets for Pan-flavivirus, Pan-alphavirus, Pan-dengue 1-4 (DENV), Zika Virus (ZIKV), West Nile virus (WNV), yellow fever virus (YFV), St Louis encephalitis virus (SLEV), tick-borne encephalitis virus (TBEV), and Japanese encephalitis virus (JEV) and chikungunya (CHIKV). The EasyScreen™ Flavivirus/Alphavirus Detection Kit is currently for Research Use Only (RUO).

About ECCMID: The 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is one of the largest European Infectious diseases meetings. The congress provides a forum for the world’s leading experts who come together to discuss the latest developments in diseases, infection control, and clinical microbiology.

Genetic Signatures CSO Presenting at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Vienna, Austria

By | Latest News | No Comments

Molecular diagnostics (MDx) company Genetic Signatures’ Chief Scientific Officer, Dr Doug Millar has been selected to present at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), to be held 22-25 April 2017 in Vienna, Austria.

The presentation will highlight Genetic Signatures’ proprietary 3base™ technology and upcoming EasyScreenTM detection kits, including the EasyScreen™ Flavivirus and Alphavirus Detection Kit. This Detection kit is designed to detect 8 of the most common Flavivirus and Alphavirus infections in the world.

Dr Millar’s oral presentation will be in Hall C Session: New Approaches in Molecular Diagnostics Virology on the 23rd April 2017 at 2.30pm (CEST).

Visit Genetic Signatures at Booth #137 at ECCMID 2017 for more information.

Click here to visit ECCMID 2017


About Flavivirus: The Flaviviridae are a family of positive, single-stranded, enveloped RNA viruses. They are found in arthropods, (primarily ticks and mosquitoes), and can occasionally infect humans.

Members of this family belong to a single genus, Flavivirus, and cause widespread morbidity and mortality throughout the world. Some of the mosquitoes-transmitted viruses include: Yellow FeverDengue FeverJapanese encephalitisWest Nile viruses and Zika Virus1.

About ECCMID: The 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is one of the largest European Infectious diseases meetings. The congress provides a forum for the world’s leading experts who come together to discuss the latest developments in diseases, infection control and clinical microbiology.

  1. The CDC website: Viral Hemorrhagic Fevers (VHFs) https://www.cdc.gov/vhf/virus-families/flaviviridae.html

Genetic Signatures’ CEO & CSO presenting at Gene Target Solutions Symposium, Sydney Australia.

By | Latest News | No Comments

Molecular diagnostics (MDx) company Genetic Signatures’ CEO Dr John Melki and CSO Dr Doug Miller will present at the inaugural Gene Target Solutions Symposium: qPCR, Past Present and Future on the 13-14th March 2017 in Sydney, Australia.

CEO Dr Melki’s presentation is entitled “History of 3base™ technology and its application in molecular diagnostics.” The presentation will highlight the background of Genetic Signatures novel technology and its utilisation in the field of Molecular Diagnostics.

The second presentation by CSO Dr Miller is entitled, “Application of 3base™ technology to the detection of diverse families of both DNA and RNA viruses.” Dr Miller will discuss the molecular applications of Genetic Signatures 3base™ technology for species identification of infectious pathogens.

Meet Genetic Signatures CEO and CSO at qPCR Symposium Australia for more information.

Click here to visit the qPCR Symposium Australia website 


About Gene Target Solutions Symposium: qPCR Symposium Australia is a conference featuring renowned International and Australian speakers. This inaugural symposium hosted by Australian owned company Gene Target Solutions, is the first and only Australian event purely dedicated to qPCR.

Genetic Signatures exhibiting at the 24th International Molecular Medicine TRI-Conference (MMTC)

By | Latest News | No Comments

Molecular diagnostics (MDx) company Genetic Signatures Ltd will exhibit at the 24th International Molecular Medicine TRI-Conference (MMTC) in San Francisco, CA on 20th–22nd February 2017.

Genetic Signatures will be exhibiting their novel products for the detection of infectious diseases, including reagents for diagnosing bacterial, viral and protozoan causes of gastroenteritis, respiratory infections and Sexually Transmitted Infections. These reagents are based on the company’s proprietary 3base™ technology, allowing for more efficient detection of infectious microorganisms.

Visit Genetic Signatures at Booth 09 at MMTC 2017 for more information.

Click here to visit the MMTC website. 


 

About MMTC 2017: MMTC also known as Tri-Con is an annual precision medicine event attracting over 3,500 senior level scientists and executives focused in the areas of Molecular Medicine specifically on Discovery, Genomics, Diagnostics and Informatics.

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3baseTM. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreenTM brand. Genetic Signatures’ proprietary MDx 3baseTM platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.